Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity (SELECT): [9] A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity (SURMOUNT-MMO): [10] Trial Finds Bimagrumab Aids Weight Loss in Patients With T2D, Obesity
It's about removing the small things that drain you
Therefore, even if a study reports a slight relative increase linked to a medication, the number of additional cases per 10,000 patients may be minimal
It is characterized by strong patent protections, high development costs, and stringent regulatory requirements that create high entry barriers
Side effects are generally mild and transient
Clinical studies show that weight loss typically continues for 6-12 months before plateauing, and discontinuing the medication often leads to weight regain